212 related articles for article (PubMed ID: 32410378)
21. [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI].
Pfannenberg C; Schwenzer N
Radiologe; 2015 Feb; 55(2):120-6. PubMed ID: 25589421
[TBL] [Abstract][Full Text] [Related]
22.
Dyrberg E; Hendel HW; Huynh THV; Klausen TW; Løgager VB; Madsen C; Pedersen EM; Pedersen M; Thomsen HS
Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
[TBL] [Abstract][Full Text] [Related]
23. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
[TBL] [Abstract][Full Text] [Related]
24. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.
Catalano OA; Daye D; Signore A; Iannace C; Vangel M; Luongo A; Catalano M; Filomena M; Mansi L; Soricelli A; Salvatore M; Fuin N; Catana C; Mahmood U; Rosen BR
Int J Oncol; 2017 Jul; 51(1):281-288. PubMed ID: 28535000
[TBL] [Abstract][Full Text] [Related]
25. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
[TBL] [Abstract][Full Text] [Related]
26. A two-way comparison of whole-body 18FDG PET-CT and whole-body contrast-enhanced MRI for distant metastasis staging in patients with malignant tumors: a meta-analysis of 13 prospective studies.
Li J; Zhou H; Zhang X; Song F; Pang X; Wei Z
Ann Palliat Med; 2020 Mar; 9(2):247-255. PubMed ID: 32233618
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Diagnostic Accuracy for TNM Stage Among Whole-Body MRI and Coregistered PET/MRI Using 1.5-T and 3-T MRI Systems and Integrated PET/CT for Non-Small Cell Lung Cancer.
Ohno Y; Takeshi Y; Takenaka D; Koyama H; Aoyagi K; Yui M
AJR Am J Roentgenol; 2020 Nov; 215(5):1191-1198. PubMed ID: 32960670
[No Abstract] [Full Text] [Related]
28. Application of whole-body MRI to detect the recurrence of lung cancer.
Lee MH; Kim SR; Park SY; Park SJ; Lee EJ; Jin GY; Lee YC
Magn Reson Imaging; 2012 Dec; 30(10):1439-45. PubMed ID: 22817957
[TBL] [Abstract][Full Text] [Related]
29. Small Cell Lung Cancer Staging: Prospective Comparison of Conventional Staging Tests, FDG PET/CT, Whole-Body MRI, and Coregistered FDG PET/MRI.
Ohno Y; Yoshikawa T; Takenaka D; Koyama H; Aoyagi K; Yui M; Oshima Y; Hamabuchi N; Tanaka Y; Shigemura C; Oota S; Nomura M; Murayama K; Inui Y; Kikukawa K; Toyama H
AJR Am J Roentgenol; 2022 May; 218(5):899-908. PubMed ID: 34877872
[No Abstract] [Full Text] [Related]
30. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
[TBL] [Abstract][Full Text] [Related]
31. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.
Michielsen K; Vergote I; Op de Beeck K; Amant F; Leunen K; Moerman P; Deroose C; Souverijns G; Dymarkowski S; De Keyzer F; Vandecaveye V
Eur Radiol; 2014 Apr; 24(4):889-901. PubMed ID: 24322510
[TBL] [Abstract][Full Text] [Related]
32. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
[TBL] [Abstract][Full Text] [Related]
33. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.
Herrmann K; Queiroz M; Huellner MW; de Galiza Barbosa F; Buck A; Schaefer N; Stolzman P; Veit-Haibach P
BMC Cancer; 2015 Dec; 15():1002. PubMed ID: 26699124
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial.
Taylor SA; Mallett S; Beare S; Bhatnagar G; Blunt D; Boavida P; Bridgewater J; Clarke CS; Duggan M; Ellis S; Glynne-Jones R; Goh V; Groves AM; Hameeduddin A; Janes SM; Johnston EW; Koh DM; Miles A; Morris S; Morton A; Navani N; O'Donohue J; Oliver A; Padhani AR; Pardoe H; Patel U; Punwani S; Quinn L; Rafiee H; Reczko K; Rockall AG; Shahabuddin K; Sidhu HS; Teague J; Thaha MA; Train M; van Ree K; Wijeyekoon S; Halligan S;
Lancet Gastroenterol Hepatol; 2019 Jul; 4(7):529-537. PubMed ID: 31080095
[TBL] [Abstract][Full Text] [Related]
36. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study.
Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Elias SG; van de Brug T; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; Greer MC; de Keizer B; Nievelstein RAJ
Eur Radiol; 2021 Mar; 31(3):1494-1504. PubMed ID: 32880696
[TBL] [Abstract][Full Text] [Related]
37. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
38. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT.
Ng SH; Chan SC; Yen TC; Liao CT; Chang JT; Ko SF; Wang HM; Lin CY; Chang KP; Lin YC
Eur Radiol; 2010 Sep; 20(9):2229-40. PubMed ID: 20393714
[TBL] [Abstract][Full Text] [Related]
40. Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer.
Adeleke S; Latifoltojar A; Sidhu H; Galazi M; Shah TT; Clemente J; Davda R; Payne HA; Chouhan MD; Lioumi M; Chua S; Freeman A; Rodriguez-Justo M; Coolen A; Vadgama S; Morris S; Cook GJ; Bomanji J; Arya M; Chowdhury S; Wan S; Haroon A; Ng T; Ahmed HU; Punwani S
BMC Med Imaging; 2019 Nov; 19(1):90. PubMed ID: 31730466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
